Moderna
Moderna is a biotechnology company that pioneered a proprietary messenger RNA (mRNA) platform to develop a new class of medicines. The company's technology functions as 'software' for life, instructing cellular machinery to produce specific proteins to prevent or treat infectious diseases, immuno-oncology, and rare genetic disorders. Their primary value proposition lies in a rapid, scalable manufacturing network and a versatile platform that can address multiple therapeutic areas using the same underlying science.
Financials
Based on Q1 2026 filing
Revenue
View metricGross Profit
View metricNet Income
View metricOperating Cash Flow
View metricFree Cash Flow
View metricEPS (Diluted)
View metricBusiness Segments
Infectious Disease Vaccines
primaryThis segment focuses on the development and commercialization of mRNA-based vaccines to prevent viral and bacterial infections. It currently serves as the company's primary revenue driver through established COVID-19 and RSV products.
Spikevax, mNEXSPIKE, mRESVIA, mRNA-1083, mRNA-1010, mRNA-1403
Retail pharmacies, Government health agencies, Healthcare providers
Oncology and Individualized Neoantigen Therapies
moderateFocuses on mRNA-based cancer vaccines and therapies designed to stimulate the immune system to recognize and attack tumor cells. This includes individualized therapies tailored to a patient's specific tumor mutations.
intismeran autogene (mRNA-4157), mRNA-4359
Oncology clinics, Research hospitals
Rare Disease and Other Therapeutics
minorDevelops mRNA therapies for rare genetic disorders where patients lack specific functional proteins. These treatments aim to provide the body with the instructions to produce the missing proteins internally.
mRNA-3927, mRNA-3705
Specialized medical centers, Rare disease patients
Segment Financials
United States — Total Revenue
View metricEurope — Total Revenue
View metricBusiness Overview
Competitive Position
Moderna is a dominant leader in the mRNA space with a first-mover advantage in mRNA vaccines and a highly integrated global manufacturing footprint.
Geographies
United States, United Kingdom, Canada, Australia, Europe
Customer Segments
Governments, Retail pharmacies, Healthcare systems
Upstream Dependencies
Nucleotide suppliers, Lipid nanoparticle raw materials, Specialized laboratory equipment, Contract research organizations
Downstream Customers
Public health departments, Wholesale pharmaceutical distributors, Retail pharmacy chains, Hospitals
Competitors & Partners
Competitors
Partners
Merck & Co.
MRK
Collaboration partner for the individualized neoantigen therapy intismeran (mRNA-4157)
Recordati
Strategic collaboration for the development and commercialization of mRNA-3927 for propionic acidemia
Pfizer
PFE
Direct competitor in the mRNA COVID-19 vaccine market
BioNTech
BNTX
Direct competitor in mRNA technology and COVID-19 vaccines
Moderna FAQ
Common questions about Moderna
Moderna is a biotechnology company that pioneered a proprietary messenger RNA (mRNA) platform to develop a new class of medicines. The company's technology functions as 'software' for life, instructing cellular machinery to produce specific proteins to prevent or treat infectious diseases, immuno-oncology, and rare genetic disorders. Their primary value proposition lies in a rapid, scalable manufacturing network and a versatile platform that can address multiple therapeutic areas using the same underlying science.
Moderna (MRNA) has a market capitalization of $18.9B and trades on NASDAQ.
Moderna generated $2.2B in trailing twelve-month revenue with a net loss of $3.2B, representing a net margin of -143.6%. Gross margin stands at 22.1%, with free cash flow of -$3.6B. These figures are based on the Q1 2026 filing.
Moderna's key competitors include Roivant Sciences Ltd. Common Shares, Alnylam Pharmaceuticals, Inc., Pfizer, and others. These companies compete in similar markets and product categories.
Moderna has approximately 5,600 employees.